

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

William M. Vollmer, Ph.D.

Committee: Pulmonary and Allergy Drugs Advisory Committee

Meeting Date: May 1, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the agenda item concerning the discussion of the efficacy of approved product Advair Diskus 500/50 (fluticasone propionate/salmeterol inhalation powder) to increase survival and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) - NDA 21007 efficacy supplement, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Employer's Related Study	Sponsor & Competing Firms	From \$100,001 to \$300,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

 /S/
Signature of SGE

 4/9/07
Date